The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1527
Sarilumab (Kevzara) for Rheumatoid Arthritis
The full article is available to subscribers Subscriber Login   

The FDA has approved the interleukin (IL)-6 inhibitor sarilumab (Kevzara – Sanofi) for second-line treatment of adults with moderately to severely active rheumatoid arthritis (RA). It is the second IL-6 inhibitor to be approved for this indication; tocilizumab (Actemra) was approved earlier.1

STANDARD TREATMENT — For initial treatment of RA, most expert clinicians prescribe a disease-modifying antirheumatic drug (DMARD) and add a nonsteroidal anti-inflammatory drug (NSAID) or a corticosteroid to control symptoms. Methotrexate is generally the DMARD of choice; hydroxychloroquine and sulfasalazine are safer alternatives that may be appropriate in the mildest cases. Guidelines generally recommend monotherapy for initial treatment of RA even in patients with moderate-to-severe disease. Some clinicians, however, may combine methotrexate with one or two other DMARDs, ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Sarilumab (Kevzara) for Rheumatoid Arthritis
Article code: 1527b
 Electronic, downloadable article - $25